Tevogen.AI

Enhancing Patient Access by Utilizing Artificial Intelligence-powered Tools

Tevogen.AI aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcel™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company’s pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs.

Proprietary Technologies

Tevogen.AI will leverage Microsoft’s digital infrastructure, scientific research, and AI expertise, along with Databricks’ data engineering capabilities, to power the development of its proprietary technologies.

PredicTcell™

A suite of AI algorithms that predict immunologically active peptide-T cell receptor interactions to enhance precision immunotherapy. Continuously refined through reinforcement learning, PredicTcell accelerates in-vivo processes and expands Tevogen Bio’s pipeline. Its growing terabyte-scale database analyzes millions of protein-peptide interactions across diseases and the human genome.

AdapTcell™

AI-driven algorithms decoding human leukocyte (HLA) antigens and T cell interactions to deepen immune system insights and reveal new therapeutic paths. As understanding grows, AdapTcell models conduct in-silico experiments that inform genetics, proteomics, and build a high-resolution HLA specificity map.

Recent Highlights

Goals

Target Detection

We are exploring ways to deploy AI-powered target detection to further accelerate our product development pace, either internally or in collaboration with others.

Reducing Failure Rates

AI could use data patterns to foresee potential adverse drug reactions early on, potentially averting costly trial failures. It might also flag efficacy concerns, guiding timely adjustments to enhance the probability of success.

Optimizing Clinical Trials

AI algorithms could analyze data to identify patients who would be most likely to respond to the investigational therapy.

Tevogen Receives $1 Million to Accelerate AI Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Tevogen Bio – August 7, 2025

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio – August 5, 2025

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

Tevogen Bio – July 18, 2025

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch

Tevogen Bio – July 16, 2025

Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Tevogen Bio – July 14, 2025

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen Bio – May 30, 2025

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

Tevogen Bio – March 7, 2025

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Tevogen Bio – January 24, 2025

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Tevogen Bio – January 23, 2025

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Tevogen Bio – December 26th, 2024

Tevogen Bio to Host Panel “AI In Biopharma: Next Frontier of Medical Innovation” During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio – December 23rd, 2024

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio – December 19th, 2024

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Tevogen Bio – November 5th, 2024

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Tevogen Bio – October 31st, 2024

Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

Tevogen Bio – October 23rd, 2024

Mittul Mehta, Head of Tevogen’s Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Tevogen Bio – February 27th, 2024

Tevogen Bio Expands Presence in Rapidly Emerging Field of Biotechnology AI: Files Patent Applications Related to AI-Driven T cell Target Identification and Receptor Engagement

Tevogen Bio – December 19th, 2023

Tevogen Bio Appoints IT Expert and Leader Mittul Mehta as Chief Information Officer and Head of Tevogen.ai Initiative

Tevogen Bio – October 23rd, 2023

Tevogen Bio Introduces Tevogen.ai to Enhance Patient Accessibility and Accelerate Innovation Leveraging Artificial Intelligence

Tevogen Bio – October 10th, 2023

Media

A healthier world is possible when lifesaving innovations are within the reach of all

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.